Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Jim Birchenough

Recent news which mentions Jim Birchenough

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir
Tickers GILD UBS
Tags Reiteration Morgan Stanley Coronavirus
From Benzinga
Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone
Tickers GILD
Tags Wells Fargo Tigress Financial Morgan Stanley
From Benzinga
Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use
Tickers GILD
Tags Analyst Color Covid/19 Market News
From Benzinga
Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook
Tickers FATE
Tags Wells Fargo Analyst Ratings Jim Birchenough
From Benzinga
Analysts Focus On Gilead's Late-Stage Data Readouts Following Mixed Q4
Tickers GILD
Tags Analyst Color Market News Top Stories
From Benzinga
Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update
Tickers AGTC BIIB NITE
Tags BIIB Biotech AGTC
From Benzinga
After Biogen's Alzheimer's Update, Wall Street Reacts
Tickers BIIB
Tags Laura Chico General BAN2401
From Benzinga
Uniqure Notches Bullish Initiation On Gene Therapy Prospects
Tickers BMY IONS QURE RHHBY
Tags General IONS Analyst Ratings
From Benzinga
Jounce Therapeutics Stock Slides On Disappointing Data, Wells Fargo Downgrades
Tickers JNCE NEWS
Tags Price Target Events Market News
From Benzinga
Bellicum Rallies After FDA Lifts Clinical Hold
Tickers BLCM NEWS
Tags Benzinga Jim Birchenough Wells Fargo
From Benzinga
Akcea Therapeutics Downgraded By Wells Fargo After Huge Run
Tickers AKCA IONS NEWS
Tags Analyst Ratings IONS General
From Benzinga
Wall Street Reacts To Celgene's Reported Interest In Juno
Tickers BLUE CART CELG JUNO
Tags Biotech Matthew Harrison CELG
From Benzinga
Arena Pharma Upgraded Ahead Of Clinical Data Release
Tickers ARNA
Tags ARNA Biotech Upgrades
From Benzinga
Infinity Pharmaceuticals Notches Upgrade Ahead Of Cancer Conference Presentation
Tickers INFI
Tags Jim Birchenough General Analyst Ratings
From Benzinga
FDA Warning Letter Buckles Intercept Pharma Shares; Wells Fargo Downgrades
Tickers ICPT NEWS
Tags Analyst Color FDA Jim Birchenough
From Benzinga
Analysts Weigh In On Gilead-Kite Pharma Deal
Tickers GILD KITE NEWS
Tags Phil Nadeau Price Target Analyst Color
From Benzinga
Clinical Hold For Regulus' RG101 Sparks A Downgrade At Wells Fargo
Tickers NEWS RGLS
Tags Price Target Analyst Color RGLS
From Benzinga
Legal Experts Weigh In On The Amgen/Regeneron Patent Case
Tickers AMGN NEWS REGN SNY
Tags Health Care News Wells Fargo
From Benzinga
Global Blood Therapeutics Shares Spiking On Analyst's Positive Outlook
Tickers GBT
Tags Price Target Movers Analyst Color
From Benzinga
Ziopharm Oncology Downgraded By BMO As 'Questions Persist'
Tickers ZIOP
Tags Downgrades Analyst Ratings Jim Birchenough
From Benzinga
BMO: Celgene Still A Buy On This 'Important Future Driver'
Tickers CELG
Tags Analyst Color CELG BMO Capital
From Benzinga
BMO Capital: Five Prime Therapeutics Still A Buy, Worth $31/Share Now
Tickers BLUE FPRX
Tags BMO Capital Analyst Color BLUE
From Benzinga
Regeneron Shares Fall Following BMO's Note Of Roche Preference
Tickers BMO REGN
Tags BMO Analyst Color Short Ideas
From Benzinga
Ariad Shares Continue to Surge Amidst Buyout Rumors
Tickers ARIA GSK LLY SHPG
Tags News Jim Birchenough US37733W1053
From Benzinga
UPDATE: BMO Capital Markets Upgrades Tesaro
Tickers TSRO
Tags Analyst Ratings Jim Birchenough Benzinga
From Benzinga
Tesaro Shares Tumble After Disappointing Data Results
Tickers TSRO
Tags Benzinga BMO Capital Markets Analyst Color
From Benzinga
UPDATE: BMO Capital Markets Reiterates on Receptos Following Solid 3Q13 Operating Results
Tickers RCPT
Tags RCPT BMO Capital Markets Analyst Color
From Benzinga
UPDATE: BMO Capital Markets Downgrades Ariad Pharmaceuticals on AP26113 Disappointment, Tempered ICLUSIG Expectations
Tickers ARIA
Tags BMO Capital Markets Analyst Color US04033A1007
From Benzinga
UPDATE: BMO Capital Markets Raises PT on Regulus Therapeutics Following 2Q13 Operating Results
Tickers RGLS
Tags Analyst Ratings Jim Birchenough Benzinga
From Benzinga
UPDATE: BMO Capital Markets Raises PT on Intercept Pharmaceuticals Following 2Q13 Operating Results
Tickers ICPT
Tags BMO Capital Markets Analyst Color Price Target
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.